State Street Holds 4.4% Of Acadia — The Drugmaker Faces A Patent Appeal

The passive holding totals 7,650,889 shares, while Acadia awaits a ruling on protection for its NUPLAZID capsule formulation.

Share
State Street Holds 4.4% Of Acadia — The Drugmaker Faces A Patent Appeal

State Street reported a 4.4% passive stake in Acadia Pharmaceuticals, which develops and sells drugs for neurological and rare diseases, in an SEC ownership disclosure filed Tuesday. The position puts State Street among the drugmaker's holders as Acadia awaits an appeal ruling over its NUPLAZID capsule formulation patent.

7.7 Million Shares, No Control Bid

State Street's reported position covered 7,650,889 common shares as of September 30, on the disclosure's beneficial-ownership basis. It reported shared voting authority over 7,263,092 shares and no sole voting authority.

State Street certified that the securities were bought and held as part of ordinary business activity, rather than for an effort to change or influence Acadia's control.

Higher Sales, Lower Profit

Acadia's third-quarter revenue reached $342.3 million, compared with $278.6 million a year earlier. Net income moved in the opposite direction: $53.5 million, versus $71.8 million.

The San Diego-based company's commercial business centers on NUPLAZID and DAYBUE. NUPLAZID has FDA approval to treat hallucinations and delusions linked to Parkinson's disease psychosis; DAYBUE treats Rett syndrome and is sold in the United States, with approvals also in Canada and Israel.

Together, the products generated $1.1 billion in net sales in 2025, compared with $957.8 million in 2024.

Two Patent Protection Dates At Stake

The Federal Circuit heard oral arguments Monday in the NUPLAZID formulation patent appeal. A district court upheld that patent in May 2025.

Acadia expects protection through February 2038 if the judgment survives the appeal. If it does not, the company expects protection through October 2030 from a separate patent and pediatric exclusivity. Acadia expects a ruling in the first half of 2027, though it said the decision has no fixed timeline.

Its clinical pipeline is led by remlifanserin for psychosis associated with Alzheimer's disease and Lewy Body Dementia.

Acadia plans to present mid-stage findings on remlifanserin for Alzheimer's disease psychosis on November 17.

Sources

More on Acadia Pharmaceuticals

All Acadia Pharmaceuticals (ACAD) coverage →